Skip to main content
Clinical Trials/NCT03707522
NCT03707522CompletedNot Applicable

The Effect of Growth Mindset Psychoeducation on Modifiable Risk Factors for Common Mental Disorders

University of Nevada, Reno1 site in 1 country162 target enrollmentStarted: June 19, 2018Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
162
Locations
1
Primary Endpoint
Generalized Anxiety Disorder-7 (GAD-7; Spitzer, Kroenke, Williams & Lowe, 2006)

Study Overview

Brief Summary

The present study aims to determine the effect of presenting psychoeducation emphasizing "growth-mindset," and information on modifiable risk factors (e.g., social contact, physical activity) on engagement with modifiable risk factors. The investigators hypothesize that psychoeducation emphasizing that mental health is malleable will increase the participant's engagement with risk factors outlined in the intervention.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Factorial
Primary Purpose
Prevention
Masking
Double (Participant, Investigator)

Eligibility Criteria

Ages
18 Years to 65 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •College freshmen

Exclusion Criteria

  • •Not fluent in English

Arms & Interventions

Growth mindset + MRF Information

Experimental

Online growth mindset interactive article followed by equal length interactive article describing the relationship between modifiable risk factors (MRF) and mental health outcomes

Intervention: Growth mindset (Behavioral)

Growth mindset + MRF Information

Experimental

Online growth mindset interactive article followed by equal length interactive article describing the relationship between modifiable risk factors (MRF) and mental health outcomes

Intervention: Modifiable risk factor (MRF) information (Behavioral)

Control + MRF information

Experimental

Online daily activity scheduling interactive article (control) followed by equal length interactive article describing the relationship between modifiable risk factors and mental health outcomes

Intervention: Modifiable risk factor (MRF) information (Behavioral)

Control + MRF information

Experimental

Online daily activity scheduling interactive article (control) followed by equal length interactive article describing the relationship between modifiable risk factors and mental health outcomes

Intervention: Control (Behavioral)

Control + Growth mindset

Experimental

Online growth mindset interactive article followed by equal length online daily activity scheduling interactive article (control)

Intervention: Growth mindset (Behavioral)

Control + Growth mindset

Experimental

Online growth mindset interactive article followed by equal length online daily activity scheduling interactive article (control)

Intervention: Control (Behavioral)

Control + Control

Placebo Comparator

2 doses online daily activity scheduling interactive article (control)

Intervention: Control (Behavioral)

Outcomes

Primary Outcomes

Generalized Anxiety Disorder-7 (GAD-7; Spitzer, Kroenke, Williams & Lowe, 2006)

Time Frame: 3 months

7-item scale, common, brief measure of anxiety symptom severity. Items consist of a 4-point Likert scale (0="Not at all" to 3="Nearly every day"). Minimum score is 0, maximum score is 21. Higher scores indicate greater anxiety symptom severity.

Patient Health Questionnaire (PHQ-9; Kroenke, Spitzer & Williams, 2001)

Time Frame: 3 months

9-item questionnaire associated containing one item for each symptom of MDD as specified by the DSM. Items consist of a 4-point Likert scale (0="Not at all" to 3="Nearly every day"). Minimum score is 0, maximum score is 27. Higher scores indicate greater depression severity.

Secondary Outcomes

  • Substance Use Measure (Lee et al., 2015)(3 months)
  • Cognitive and Behavioral Avoidance Scale (CBAS, Ottenbreit & Dobson, 2003)(3 months)
  • Positive Reframing; Brief COPE (B-COPE; Carver, 1997)(3 months)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Martha Zimmermann

Principal Investigator

University of Nevada, Reno

Study Sites (1)

Loading locations...

Similar Trials